A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors
Tabernero, Josep × Dirix, Luc Schöffski, Patrick Cervantes, Andrés Lopez-Martin, Jose Antonio Capdevila, Jaume van Beijsterveldt, Ludy Platero, Suso Hall, Brett Yuan, Zhilong Knoblauch, Roland Zhuang, Sen Hong #
Association for Cancer Research
Clinical Cancer Research vol:17 issue:19 pages:6313-6321
Originally isolated on the basis of its ability to induce p53, serdemetan showed potent activity in various preclinical models, inducing S-phase arrest and apoptosis in TP53 wild-type and mutant tumors. This study evaluated the safety and tolerability of serdemetan, determined the pharmacokinetic and pharmacodynamic profiles, and identified a recommended phase II dose.